Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

NANot yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2030

Conditions
Myeloproliferative NeoplasmMyeloproliferative Disorders
Interventions
BIOLOGICAL

Additional blood sampling

At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis

Trial Locations (16)

24019

CH de Périgueux, Service Oncologie Hématologie, Périgueux

29609

CHU de Brest, Service Hématologie et Hémostase Clinique, Brest

29672

CH des Pays de Morlaix, Service Onco-Hématologie, Morlaix

33505

CH de Libourne, Service Hématologie, Libourne

33600

CHU de Bordeaux, Service Hématologie Biologique, Bordeaux

CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire, Bordeaux

44093

CHU de Nantes, Service Hématologie Clinique, Nantes

44202

Hôpital Privé du Confluent, Service Hématologie, Nantes

49933

CHU d'Angers, Service des maladies du Sang, Angers

59100

CH de Roubaix, Service Hématologie, Roubaix

64100

CH de la Côte Basque, Service Hématologie, Bayonne

75010

APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris

85925

CHD de Vendée, Service Onco-hématologie, La Roche-sur-Yon

87042

CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire, Limoges

94010

APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire, Créteil

94270

APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire, Le Kremlin-Bicêtre

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT07119970 - Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE) | Biotech Hunter | Biotech Hunter